Actio Biosciences launches trial of precision medicine for rare childhood epilepsy
Actio Biosciences has launched a Phase 1b/2 clinical trial of ABS-1230, an investigational precision medicine for KCNT1-related epilepsy. KCNT1-related epilepsy is a…
Actio Biosciences has launched a Phase 1b/2 clinical trial of ABS-1230, an investigational precision medicine for KCNT1-related epilepsy. KCNT1-related epilepsy is a…